Clinical Chemistry Siemens Point of Care - Urinalysis
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 48: 1781-1784, 2002;
This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (39)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pai, J. K.
Right arrow Articles by Rimm, E. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pai, J. K.
Right arrow Articles by Rimm, E. B.
Related Collections
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors
(Clinical Chemistry. 2002;48:1781-1784.)
© 2002 American Association for Clinical Chemistry, Inc.


Technical Briefs

Stability of Novel Plasma Markers Associated with Cardiovascular Disease: Processing within 36 Hours of Specimen Collection

Jennifer K. Pai1,3a, Gary C. Curhan1,5, Carolyn C. Cannuscio7, Nader Rifai6,8, Paul M. Ridker3,4,6 and Eric B. Rimm1,2,5

Departments of
1 Epidemiology and
2 Nutrition, Harvard School of Public Health, Boston, MA 02115
Divisions of
3 Preventive Medicine and
4 Cardiology,
5 Channing Laboratory, Department of Medicine, and
6 Center for Cardiovascular Disease Prevention, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115
7 Merck & Co., Inc., West Point, PA 19422

8 Department of Pathology, Children’s Hospital Medical Center and Harvard Medical School, Boston, MA 02115

aaddress correspondence to this author at: Harvard School of Public Health, Department of Epidemiology, 677 Huntington Ave., 9th Floor, Kresge Bldg., Boston, MA 02115; fax 617-566-7805, e-mail jpai{at}hsph.harvard.edu

Plasma markers are ideally measured prospectively because marker concentrations may change after diagnosis with disease. In many large prospective studies, such as the Nurses’ Health Study (1) and Health Professionals Follow-up Study (2), blood samples are collected, placed on ice, and mailed back to the central laboratory for processing via overnight or next-day mail service. Because economic constraints typically lead researchers to collect only one sample per study participant (3)(4), it is important to determine the time frame within which markers remain stable and to optimize the methods for handling and processing the sample. Although many studies have examined marker stability after long-term storage, few studies have assessed the impact of transport conditions on whole blood not immediately processed.

We selected a series of lipid and novel inflammatory markers whose concentrations have been shown or have been suspected to influence the risk of cardiovascular disease: C-reactive protein (CRP), fibrinogen, lipoprotein (a) [Lp(a)], apolipoprotein B (apoB), intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), p-selectin, von Willebrand factor (vWf), oxidized LDL (oxLDL), anti-cardiolipin antibodies (aCLAbs), tumor necrosis factor receptors I and II (TNF-RI and TNF-RII), and matrix metalloproteinase-1 (MMP-1) (5)(6)(7)(8)(9)(10)(11)(12)(13). The purpose of this study was to evaluate the stability of selected novel markers of cardiovascular disease under time and temperature conditions that simulated sample transport by mail for up to 36 h before processing.

We included 17 premenopausal women, 25–45 years of age, who had responded to a recruitment advertisement. Blood samples were collected from each woman into three 15-mL Vacutainers containing sodium heparin and placed on ice until processing. The time to processing was defined as the time from when the samples were first placed on ice until they were centrifuged to separate the plasma from the cells, aliquoted into 2-mL tubes, and finally stored in liquid nitrogen (-140 °C) until analysis. One sample was processed immediately and defined as the baseline at 0 h. The second and third samples were sealed in styrofoam packing materials with a cold pack, as was used in our main study. The second sample was processed 24 h later to simulate overnight mail service, and the third sample was processed 36 h later to simulate next-day mail service. One sample from each time point, from each individual, was then sent to the laboratory for analysis. This project was approved by the Institutional Review Board at the Harvard School of Public Health, and all participants gave informed consent for the blood.

All 13 biomarkers were assayed by the laboratory of Dr. Nader Rifai (The Children’s Hospital, Boston, MA). apoB and fibrinogen were measured with immunoturbidimetric assays on the Hitachi 911 analyzer (Roche Diagnostics), using reagents and calibrators from Wako (Wako Chemicals USA) and Kamiya Biomedical Co., respectively. CRP and Lp(a) were measured spectrophotometrically on the Hitachi 911 analyzer (Roche Diagnostics), using reagents and calibrators from Denka Seiken. Soluble ICAM-1 and VCAM-1, p-selectin, TNF-RI, TNF-RII, and MMP-1 were measured with ELISAs from R&D Systems. aCLAbs were screened using an ELISA from Alpco (Alpco Diagnostics). oxLDL was measured with an ELISA from Mercodia (Alpco Diagnostics), and vWf was measured with an ELISA from American Diagnostica. All samples were thawed together and analyzed in a single analytical run to minimize the contribution of run-to-run variability. To ensure blinding of laboratory personnel, each sample was assigned a different identification number and placed randomly in the analysis batch with respect to the three different processing times.

All markers were log-transformed to improve normality. The distribution of each marker was expressed as the mean concentration and 95% confidence intervals derived from the SD of all women at each time point. The mean differences were calculated using the paired t-test. For the convenience of the reader, results were transformed back to the original scale, and geometric means, 95% confidence intervals, and differences are presented. The between- and within-person variances were calculated by ANOVA, accounting for repeated measures. We calculated intraclass correlation coefficients (ICCs) by dividing the between-person variance by the sum of the between- and within-person variances (14). ICCs provide the proportion of the total variance that can be explained by the between-person variance.

Shown in Table 1 are the mean and 95% confidence interval for each inflammatory marker at 0, 24, and 36 h and the mean differences over time for 0–24 h and 0–36 h. The mean values for CRP, apoB, oxLDL, ICAM-1, VCAM-1, TNF-RII, and aCLAbs were very stable and statistically consistent up to 36 h until processing. Lp(a) and fibrinogen showed some degradation after initial collection, whereas TNF-RI significantly increased with longer time to processing. The delay in processing also had significant effects on p-selectin, vWf, and MMP-1.


View this table:
[in this window]
[in a new window]
 
Table 1. Selected plasma marker values1 at 0, 24, and 36 h until sample processing.

An ICC of 0.99 means that 99% of the variation is explained by between-subject variation and 1% is explained by within-subject variation. Therefore, a low within-subject variation would suggest minimal instability attributable to processing methods. An ICC <0.4 indicates poor reproducibility, 0.4 < ICC < 0.75 indicates fair to good reproducibility, and ICC >0.75 indicates excellent reproducibility (14).

The majority of these biological markers had good to excellent reproducibility, with ICCs of 0.59–0.99. The ICCs for CRP, Lp(a), and aCLAbs were all >0.9 for 0–24 and 0–36 h. Fig. 1 shows the stability of CRP between 0 and 24 h compared with 0 and 36 h. oxLDL, TNF-RI, apoB, TNF-RII, and ICAM-1 all had ICCs that were >0.75 for 0–24 and 0–36 h. VCAM-1 exhibited slightly lower reliability, with ICCs for 0–24 and 0–36 h of 0.59 and 0.61, respectively. Fibrinogen had low ICCs of 0.27 for 0–24 and 0.48 for 0–36 h. p-Selectin and MMP-1 had very poor ICCs of 0.14 and 0.16, respectively, at 0–24 h. The 0–36 h differences for p-selectin and MMP-1, and the 0–24 h differences for vWf yielded negative ICCs, which demonstrates the instability of these markers when not processed immediately.



View larger version (14K):
[in this window]
[in a new window]
 
Figure 1. Correlation of log-transformed CRP at 0–24 h ({circ}) compared with 0–36 h (•).

Few studies have examined time-to-processing conditions up to 36 h. The majority of our markers showed excellent stability and reproducibility when processed within 36 h of collection time and were not significantly different from samples processed immediately after venipuncture. In our study, fibrinogen concentrations did not change significantly up to 24 h, but had changed significantly by 36 h. Two extreme values likely had skewed these results because previous work had demonstrated somewhat more stability. Other groups have reported concentrations that did not vary significantly from baseline for at least 1 week in whole blood stored at 4 °C (15) and changes of <10% after 7 days in plasma stored at 6 °C (16). An additional analysis that excluded those two outlier points improved our intraclass correlation to 0.51 for 0–24 h and 0.53 for 0–36 h. Nonetheless, despite improvements and attempts to standardize assays over time, intra- and interassay CVs for fibrinogen have remained high (17). p-Selectin and vWf showed little stability from 0 to 24 to 36 h. At 4 °C, platelets probably continue to produce selectin (18) and binding of vWf may be impaired (19).

Our results for apoB showed no significant changes up to 36 h and were consistent with those reported previously. Hankinson et al. (4) demonstrated stability of apoB in blood chilled (~9 °C) up to 24 and 48 h until time to processing. Although long-term storage has been studied (20)(21), the stability of Lp(a) in samples with a time to processing of up to 36 h has not been reported. We found that Lp(a) concentrations were stable up until 24 h from venipuncture, but less so when processing was delayed up to 36 h.

Although aCLAbs are influenced by storage and thawing procedures (22), our study showed that aCLAbs are stable on ice for up to 36 h. Temperature dependence had been shown for ICAM-1 and VCAM-1 from frozen cells (23). However, neither of those two markers in serum had been explored for time-to-processing stability. Although short-term processing stability had not been assessed for CRP, Kayaba et al. (24) examined 5-year intraindividual correlation for CRP and reported reasonable reliability. This suggests that CRP would be stable when plasma is stored at or below -80 °C. To our knowledge, MMP-1, oxLDL, TNF-RI, and TNF-RII have not been studied for time-to-processing stability, temperature dependence, or long-term stability. MMP-1 showed more variation from 0 to 24 h than any other marker and would not be stable if kept on ice for 24 h.

CRP, oxLDL, apoB, aCLAbs, TNF-RII, ICAM-1, and VCAM-1 would all remain stable if kept on ice for 36 h until processing. TNF-RI, Lp(a), and fibrinogen appear to be stable up to 24 h until processing, whereas p-selectin, vWf, and MMP-1 should be processed immediately.


Acknowledgments

We thank Alan Paciorek for coordinating sample collection and laboratory management. This research was funded by an unrestricted grant from Merck & Co., Inc. Jennifer Pai is funded by an institutional training grant from the National Heart, Lung, and Blood Institute (HL07575).


References

  1. Colditz GA. The Nurses’ Health Study: a cohort of US women followed since 1976. J Am Med Womens Assoc 1995;50:40-44.
  2. Michaud DS, Spiegelman D, Clinton SK, Rimm EB, Curhan GC, Willett WC, et al. Fluid intake and the risk of bladder cancer in men. N Engl J Med 1999;340:1390-1397.[Abstract/Free Full Text]
  3. Michaud DS, Manson JE, Spiegelman D, Barbieri RL, Sepkovic DW, Bradlow HL, et al. Reproducibility of plasma and urinary sex hormone levels in premenopausal women over a one-year period. Cancer Epidemiol Biomarkers Prev 1999;8:1059-1064.[Abstract/Free Full Text]
  4. Hankinson SE, London SJ, Chute CG, Barbieri RL, Jones L, Kaplan LA, et al. Effect of transport conditions on the stability of biochemical markers in blood. Clin Chem 1989;35:2313-2316.[Abstract/Free Full Text]
  5. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-Reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843.[Abstract/Free Full Text]
  6. Malik I, Danesh J, Whincup P, Bhatia V, Papacosta O, Walker M, et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet 2001;358:971-976.[Web of Science][Medline] [Order article via Infotrieve]
  7. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285:2481-2485.[Abstract/Free Full Text]
  8. Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Yudkin JS, Nijpels G, et al. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol 1999;19:3071-3078.[Abstract/Free Full Text]
  9. Knox JB, Sukhova GK, Whittemore AD, Libby P. Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases. Circulation 1997;95:205-212.[Abstract/Free Full Text]
  10. Chu NF, Spiegelman D, Rifai N, Hotamisligil GS, Rimm EB. Glycemic status and soluble tumor necrosis factor receptor levels in relation to plasma leptin concentrations among normal weight and overweight US men. Int J Obes Relat Metab Disord 2000;24:1085-1092.[Web of Science][Medline] [Order article via Infotrieve]
  11. Holvoet P, Mertens A, Verhamme P, Bogaerts K, Beyens G, Verhaeghe R, et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2001;21:844-848.[Abstract/Free Full Text]
  12. Srinivasan SR, Berenson GS. Serum apolipoproteins A-I and B as markers of coronary artery disease risk in early life: the Bogalusa Heart Study. Clin Chem 1995;41:159-164.[Abstract/Free Full Text]
  13. Vaarala O, Manttari M, Manninen V, Tenkanen L, Puurunen M, Aho K, et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995;91:23-27.[Abstract/Free Full Text]
  14. Rosner BA. Fundamentals of biostatistics, 5th ed 2000:563 Duxbury Thomson Learning Pacific Grove, CA. .
  15. Nilsson L, Hedner U, Nilsson IM, Robertson B. Shelf-life of bank blood and stored plasma with special reference to coagulation factors. Transfusion 1983;23:377-381.[Web of Science][Medline] [Order article via Infotrieve]
  16. Heil W, Grunewald R, Amend M, Heins M. Influence of time and temperature on coagulation analytes in stored plasma. Clin Chem Lab Med 1998;36:459-462.[Web of Science][Medline] [Order article via Infotrieve]
  17. Ridker PM. Evaluating novel cardiovascular risk factors: can we better predict heart attacks?. Ann Intern Med 1999;130:933-937.[Abstract/Free Full Text]
  18. Mondoro TH, Shafer BC, Vostal JG. Restoration of in vitro responses in platelets stored in plasma. Am J Clin Pathol 1999;111:693-699.[Web of Science][Medline] [Order article via Infotrieve]
  19. Lozano M, Estebanell E, Cid J, Diaz-Ricart M, Mazzara R, Ordinas A, et al. Platelet concentrates prepared and stored under currently optimal conditions: minor impact on platelet adhesive and cohesive functions after storage. Transfusion 1999;39:951-959.[Web of Science][Medline] [Order article via Infotrieve]
  20. Simo JM, Camps J, Vilella E, Gomez F, Paul A, Joven J. Instability of lipoprotein(a) in plasma stored at -70 °C: effects of concentration, apolipoprotein(a) genotype, and donor cardiovascular disease. Clin Chem 2001;47:1673-1678.[Abstract/Free Full Text]
  21. Evans RW, Sankey SS, Hauth BA, Sutton-Tyrrell K, Kamboh MI, Kuller LH. Effect of sample storage on quantitation of lipoprotein(a) by an enzyme-linked immunosorbent assay. Lipids 1996;31:1197-1203.[Web of Science][Medline] [Order article via Infotrieve]
  22. Brey RL, Cote SA, McGlasson DL, Triplett DA, Barna LK. Effects of repeated freeze-thaw cycles on anticardiolipin antibody immunoreactivity. Am J Clin Pathol 1994;102:586-588.[Web of Science][Medline] [Order article via Infotrieve]
  23. Eberl T, Amberger A, Herold M, Hengster P, Steurer W, Hochleitner BW, et al. Expression of stress proteins, adhesion molecules, and interleukin-8 in endothelial cells after preservation and reoxygenation. Cryobiology 1999;38:106-118.[Medline] [Order article via Infotrieve]
  24. Kayaba K, Ishikawa S, Gotoh T, Nago N, Kajii E, Nakamura Y, et al. Five-year intra-individual variability in C-reactive protein levels in a Japanese population-based study: the Jichi Medical School Cohort Study at Yamato, 1993–1998. Jpn Circ J 2000;64:303-308.[Medline] [Order article via Infotrieve]



The following articles in journals at HighWire Press have cited this article:


Home page
Eur Heart JHome page
M. K. Jensen, E. B. Rimm, K. J. Mukamal, A. C. Edmondson, D. J. Rader, U. Vogel, A. Tjonneland, T. I.A. Sorensen, E. B. Schmidt, and K. Overvad
The T111I variant in the endothelial lipase gene and risk of coronary heart disease in three independent populations
Eur. Heart J., July 1, 2009; 30(13): 1584 - 1589.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. Cassidy, S. E. Chiuve, J. E. Manson, K. M. Rexrode, C. J. Girman, and E. B. Rimm
Potential Role for Plasma Placental Growth Factor in Predicting Coronary Heart Disease Risk in Women
Arterioscler. Thromb. Vasc. Biol., January 1, 2009; 29(1): 134 - 139.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
R. Cangemi, L. Loffredo, R. Carnevale, L. Perri, M. P. Patrizi, V. Sanguigni, P. Pignatelli, and F. Violi
Early decrease of oxidative stress by atorvastatin in hypercholesterolaemic patients: effect on circulating vitamin E
Eur. Heart J., January 1, 2008; 29(1): 54 - 62.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
J. Hartweg, M. Gunter, R. Perera, A. Farmer, C. Cull, C. Schalkwijk, A. Kok, H. Twaalfhoven, R. Holman, and A. Neil
Stability of Soluble Adhesion Molecules, Selectins, and C-Reactive Protein at Various Temperatures: Implications for Epidemiological and Large-Scale Clinical Studies
Clin. Chem., October 1, 2007; 53(10): 1858 - 1860.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
J. K. Pai, J. E. Manson, K. M. Rexrode, C. M. Albert, D. J. Hunter, and E. B. Rimm
Complement factor H (Y402H) polymorphism and risk of coronary heart disease in US men and women
Eur. Heart J., June 1, 2007; 28(11): 1297 - 1303.
[Abstract] [Full Text] [PDF]


Home page
Br. J. Radiol.Home page
M Wildgruber, W Weiss, H Berger, H-H Eckstein, O Wolf, and P Heider
Early endothelial and haematological response to cryoplasty compared with balloon angioplasty of the superficial femoral artery a pilot study
Br. J. Radiol., June 1, 2007; 80(954): 430 - 436.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
E. Lopez-Garcia, R. M van Dam, L. Qi, and F. B Hu
Coffee consumption and markers of inflammation and endothelial dysfunction in healthy and diabetic women.
Am. J. Clinical Nutrition, October 1, 2006; 84(4): 888 - 893.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
T. Wu, W. C. Willett, N. Rifai, I. Shai, J. E. Manson, and E. B. Rimm
Is Plasma Oxidized Low-Density Lipoprotein, Measured With the Widely Used Antibody 4E6, an Independent Predictor of Coronary Heart Disease Among U.S. Men and Women?
J. Am. Coll. Cardiol., September 5, 2006; 48(5): 973 - 979.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
L. B. Link and J. S. Jacobson
Effect of delayed processing on high-sensitivity C-reactive protein.
Clin. Chem., April 1, 2006; 52(4): 787 - 788.
[Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
M. K Jensen, P. Koh-Banerjee, M. Franz, L. Sampson, M. Gronbaek, and E. B Rimm
Whole grains, bran, and germ in relation to homocysteine and markers of glycemic control, lipids, and inflammation 1
Am. J. Clinical Nutrition, February 1, 2006; 83(2): 275 - 283.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
K. J. Mukamal, M. K. Jensen, M. Gronbaek, M. J. Stampfer, J. E. Manson, T. Pischon, and E. B. Rimm
Drinking Frequency, Mediating Biomarkers, and Risk of Myocardial Infarction in Women and Men
Circulation, September 6, 2005; 112(10): 1406 - 1413.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
I. Shai, E. B. Rimm, S. E. Hankinson, C. Cannuscio, G. Curhan, J. E. Manson, N. Rifai, M. J. Stampfer, and J. Ma
Lipoprotein (a) and coronary heart disease among women: beyond a cholesterol carrier?
Eur. Heart J., August 2, 2005; 26(16): 1633 - 1639.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
C. Meisinger, J. Baumert, N. Khuseyinova, H. Loewel, and W. Koenig
Plasma Oxidized Low-Density Lipoprotein, a Strong Predictor for Acute Coronary Heart Disease Events in Apparently Healthy, Middle-Aged Men From the General Population
Circulation, August 2, 2005; 112(5): 651 - 657.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
I. Shai, M. B. Schulze, J. E. Manson, K. M. Rexrode, M. J. Stampfer, C. Mantzoros, and F. B. Hu
A Prospective Study of Soluble Tumor Necrosis Factor-{alpha} Receptor II (sTNF-RII) and Risk of Coronary Heart Disease Among Women With Type 2 Diabetes
Diabetes Care, June 1, 2005; 28(6): 1376 - 1382.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
E. Lopez-Garcia, M. B. Schulze, J. B. Meigs, J. E. Manson, N. Rifai, M. J. Stampfer, W. C. Willett, and F. B. Hu
Consumption of Trans Fatty Acids Is Related to Plasma Biomarkers of Inflammation and Endothelial Dysfunction
J. Nutr., March 1, 2005; 135(3): 562 - 566.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
Y. T. van der Schouw, L. Sampson, W. C. Willett, and E. B. Rimm
The Usual Intake of Lignans but Not That of Isoflavones May Be Related to Cardiovascular Risk Factors in U.S. Men
J. Nutr., February 1, 2005; 135(2): 260 - 266.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
J. K. Pai, T. Pischon, J. Ma, J. E. Manson, S. E. Hankinson, K. Joshipura, G. C. Curhan, N. Rifai, C. C. Cannuscio, M. J. Stampfer, et al.
Inflammatory Markers and the Risk of Coronary Heart Disease in Men and Women
N. Engl. J. Med., December 16, 2004; 351(25): 2599 - 2610.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
I. Shai, E. B. Rimm, S. E. Hankinson, G. Curhan, J. E. Manson, N. Rifai, M. J. Stampfer, and J. Ma
Multivariate Assessment of Lipid Parameters as Predictors of Coronary Heart Disease Among Postmenopausal Women: Potential Implications for Clinical Guidelines
Circulation, November 2, 2004; 110(18): 2824 - 2830.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
E. L. Knight, E. B. Rimm, J. K. Pai, K. M. Rexrode, C. C. Cannuscio, J. E. Manson, M. J. Stampfer, and G. C. Curhan
Kidney Dysfunction, Inflammation, and Coronary Events: A Prospective Study
J. Am. Soc. Nephrol., July 1, 2004; 15(7): 1897 - 1903.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
E. Lopez-Garcia, M. B. Schulze, J. E. Manson, J. B. Meigs, C. M. Albert, N. Rifai, W. C. Willett, and F. B. Hu
Consumption of (n-3) Fatty Acids Is Related to Plasma Biomarkers of Inflammation and Endothelial Activation in Women
J. Nutr., July 1, 2004; 134(7): 1806 - 1811.
[Abstract] [Full Text]


Home page
Am. J. Clin. Nutr.Home page
D. Mozaffarian, T. Pischon, S. E Hankinson, N. Rifai, K. Joshipura, W. C Willett, and E. B Rimm
Dietary intake of trans fatty acids and systemic inflammation in women
Am. J. Clinical Nutrition, April 1, 2004; 79(4): 606 - 612.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
T. Pischon, S. E. Hankinson, G. S. Hotamisligil, N. Rifai, W. C. Willett, and E. B. Rimm
Habitual Dietary Intake of n-3 and n-6 Fatty Acids in Relation to Inflammatory Markers Among US Men and Women
Circulation, July 15, 2003; 108(2): 155 - 160.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
E. J. Giltay, J. M. Geleijnse, E. G. Schouten, M. B. Katan, and D. Kromhout
High Stability of Markers of Cardiovascular Risk in Blood Samples
Clin. Chem., April 1, 2003; 49(4): 652 - 655.
[Full Text] [PDF]


This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (39)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pai, J. K.
Right arrow Articles by Rimm, E. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pai, J. K.
Right arrow Articles by Rimm, E. B.
Related Collections
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS